Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?

Amer M Zeidan Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Johns Hopkins University, Baltimore, MD, USA. [email protected]; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Johns Hopkins University, Baltimore, MD, USA. [email protected]

Steven D Gore Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Johns Hopkins University, Baltimore, MD, USA. [email protected]; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Johns Hopkins University, Baltimore, MD, USA. [email protected]

Rami S Komrokji Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA; Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Abstract

Evaluation of: Platzbecker U, Braulke F, Kündgen A et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a Phase I study. Leukemia doi:10.1038/leu.2013.26 (2013) (Epub ahead of print).

High-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML) with deletions of long arm of chromosome 5 (del[5q]) are characterized by rapid progression and poor survival. The majority of these patients are elderly with comorbidities, therefore limiting the use of intensive therapies which, even if used, unfortunately yield low responses. While azacitidine prolongs survival in patients with HR-MDS by a median of 9.5 months, responses only occur in less than half of the patients, and azacitidine therapy is not curative, with most patients relapsing within 2 years. Therefore, strategies to improve outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and AML with del(5q). Early-phase trials in HR-MDS without del(5q) suggest increased activity with a concurrent azacitidine–lenalidomide combination. In this article, we review the results of a Phase I trial of a sequential azacitidine–lenalidomide combination approach in patients with HR-MDS and AML with del(5q) abnormality.

Keywords::

Financial & competing interests disclosure

RS Komrokji has served on the speakers’ bureau for Celgene, and SD Gore owned stocks in Celgene until August 2011. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?

Information for

Open access

Opportunities

Help and information

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?

Abstract

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature